Accueil
Bourse
Actions Paris

Consensus des Analystes Sanofi

Cotation du 26/01/2022 à 17h38 Sanofi +1,63% 91,940€

Objectif de cours au 26/01/2022

107,274 €
Potentiel de +17%
cours actuel 91,940€

Note médiane des 26 analystes

1,8
5 Vendre 4 Alléger 3 Conserver 2 Renforcer 1 Acheter

Evolution des recommandations

Recommandations 26/01/2021 26/04/2021 26/07/2021 26/10/2021 26/01/2022
Acheter 11 11 10 11 13
Renforcer 8 7 8 7 7
Conserver 8 7 7 7 5
Alléger - - - - -
Vendre 1 1 1 1 1
Nb d'analystes 28 26 26 26 26
Note Médiane 2,00 1,96 2,00 1,96 1,81
Historique des objectifs 100,377€ 100,646€ 102,630€ 105,072€ 107,274€

Prévisions

2020 2021 2022
Chiffre d'affaires 36 041,00 37 786,39 40 205,81
EBITDA 11 443,00 11 666,59 13 083,27
EBIT 9 762,00 10 607,70 11 957,62
Bénéfice net par action - - -
Résultat Net 12 314,00 6 139,28 7 395,13
Flux de trésorerie disponible 6 982,00 7 125,39 8 131,89
Dette nette 8 789,00 9 924,89 6 806,48
PER 5,90 6,52 7,33
Copyright ©2022, S&P Global Market Intelligence. Reproduction of CIQ Estimates in any form is prohibited except with the prior written permission of S&P Global Market Intelligence. CIQ Estimates are not investment advice and a reference to a particular investment or security, a credit rating or any observation concerning a security or investment provided in CIQ Estimates is not a recommendation to buy, sell or hold such investment or security or make any other investment decisions. S&P Global Market Intelligence, its affiliates and their third-party providers (together, “S&P Global”) do not guarantee the accuracy, adequacy, completeness or availability of any information and are not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P GLOBAL DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P Global be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of CIQ Estimates.

Actualités Sanofi

Aucune actualité disponible.
Plus d'actualités